Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute inflammatory arthritis

Interleukin-1 blockade: a magic wand for gout?

Nature Reviews Rheumatology volume 5, pages 594–596 (2009)Cite this article

Insight into the immunopathogenesis of crystal-induced inflammation has opened the door to a new approach to therapy. Could interleukin-1 antagonists be the answer to managing acute gout?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Richette, P. & Bardin, T. Gout. Lancet doi:10.1016/S0140–6736(09)60883–7.

  2. Annemans, L. et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann. Rheum. Dis. 67, 960–966 (2008).

    Article  CAS  Google Scholar 

  3. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).

    Article  CAS  Google Scholar 

  4. Jordan, K. M. et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372–1374 (2007).

    Article  Google Scholar 

  5. Janssens, H. J., Janssen, M., van de Lisdonk, E. H., van Riel, P. L. & van Weel, C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 371, 1854–1860 (2008).

    Article  CAS  Google Scholar 

  6. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).

    Article  CAS  Google Scholar 

  7. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).

    Article  Google Scholar 

  8. Terkeltaub, R. et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomized, single-blind pilot study. Ann. Rheum. Dis. 68, 1613–1617 (2009).

    Article  CAS  Google Scholar 

  9. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443–2452 (2008).

    Article  CAS  Google Scholar 

  10. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416–2425 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology Department, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France

    Thomas Bardin

Authors
  1. Thomas Bardin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Bardin.

Ethics declarations

Competing interests

T. Bardin has acted as a consultant for Novartis and Ipsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bardin, T. Interleukin-1 blockade: a magic wand for gout?. Nat Rev Rheumatol 5, 594–596 (2009). https://doi.org/10.1038/nrrheum.2009.213

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.213

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing